

### ICMJE Form for Disclosure of Potential Conflicts of Interest

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

## Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## **Intellectual Property.**

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Rimola 1



# **ICMJE Form for Disclosure of Potential Conflicts of Interest**

Section 1. Identifying Information	mation			
identifying infor	illation			
1. Given Name (First Name) Jordi	2. Surname (Last Name) Rimola		3. Date 14-December-2016	
4. Are you the corresponding author?	✓ Yes No			
5. Manuscript Title 2016-2017_ECCO_Annual_Disclosure				
6. Manuscript Identifying Number (if you l	know it)			
Section 2. The Work Under 0	Consideration for Publica	ntion		
Did you or your institution <b>at any time</b> recany aspect of the submitted work (includir statistical analysis, etc.)?  Are there any relevant conflicts of inte If yes, please fill out the appropriate in	ng but not limited to grants, data rest?  Yes  No formation below. If you have	monitoring board, stud	y design, manuscript preparation,	
Excess rows can be removed by pressi	ng the "X" button.			
Name of Institution/Company	Grant	Financial Other?	Comments	
	rees 3u	pport		
Robarts Clinical Trials	rees Su			
Robarts Clinical Trials				
Fakeda				
Fakeda Figenix				
Fakeda Figenix				
Fakeda Figenix Bioclinica				
Fakeda Figenix Bioclinica	l activities outside the susting in the table to indicate wheteribed in the instructions. Use eport relationships that were	bmitted work.  ther you have financia one line for each enti	ty; add as many lines as you ne	ed by

Rimola 2



# **ICMJE Form for Disclosure of Potential Conflicts of Interest**

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Rimola 3